CA2216057A1 - Gene contenant des microsatellites polymorphiques de type cag, diagnostic de maladies psychiatriques et usages therapeutiques de ce gene - Google Patents
Gene contenant des microsatellites polymorphiques de type cag, diagnostic de maladies psychiatriques et usages therapeutiques de ce gene Download PDFInfo
- Publication number
- CA2216057A1 CA2216057A1 CA 2216057 CA2216057A CA2216057A1 CA 2216057 A1 CA2216057 A1 CA 2216057A1 CA 2216057 CA2216057 CA 2216057 CA 2216057 A CA2216057 A CA 2216057A CA 2216057 A1 CA2216057 A1 CA 2216057A1
- Authority
- CA
- Canada
- Prior art keywords
- gene
- schizophrenia
- patients
- allelic variants
- hgtl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 65
- 208000020016 psychiatric disease Diseases 0.000 title abstract description 10
- 238000003745 diagnosis Methods 0.000 title abstract description 9
- 230000001225 therapeutic effect Effects 0.000 title description 4
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 56
- 238000011282 treatment Methods 0.000 claims abstract description 15
- 238000004393 prognosis Methods 0.000 claims abstract description 6
- 239000003176 neuroleptic agent Substances 0.000 claims description 40
- 230000000701 neuroleptic effect Effects 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 24
- 230000004044 response Effects 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 14
- 239000000523 sample Substances 0.000 claims description 14
- 241000282414 Homo sapiens Species 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 230000004904 long-term response Effects 0.000 claims description 6
- 230000001123 neurodevelopmental effect Effects 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 208000014644 Brain disease Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 3
- 208000017194 Affective disease Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 230000008238 biochemical pathway Effects 0.000 claims description 2
- 208000028683 bipolar I disease Diseases 0.000 claims description 2
- 210000004602 germ cell Anatomy 0.000 claims description 2
- 210000001082 somatic cell Anatomy 0.000 claims description 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 108700026220 vif Genes Proteins 0.000 abstract description 2
- 108700028369 Alleles Proteins 0.000 description 44
- 230000000698 schizophrenic effect Effects 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 15
- 201000010099 disease Diseases 0.000 description 12
- 230000002068 genetic effect Effects 0.000 description 10
- 108091023040 Transcription factor Proteins 0.000 description 8
- 102000040945 Transcription factor Human genes 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 208000028017 Psychotic disease Diseases 0.000 description 7
- 230000004043 responsiveness Effects 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
- 230000006866 deterioration Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229930002330 retinoic acid Natural products 0.000 description 4
- 229960001727 tretinoin Drugs 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 2
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108091060211 Expressed sequence tag Proteins 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000002869 basic local alignment search tool Methods 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000001667 episodic effect Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003061 neural cell Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229920000155 polyglutamine Polymers 0.000 description 2
- 108010040003 polyglutamine Proteins 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001755 vocal effect Effects 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 235000001270 Allium sibiricum Nutrition 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000033882 Genetic Anticipation Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108700011325 Modifier Genes Proteins 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- WZQNNALXEJBHLB-UHFFFAOYSA-N O.OOO Chemical compound O.OOO WZQNNALXEJBHLB-UHFFFAOYSA-N 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000001544 dysphoric effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000010855 neuropsychological testing Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000016021 phenotype Diseases 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000013138 pruning Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 230000009295 sperm incapacitation Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2216057 CA2216057A1 (fr) | 1997-09-19 | 1997-09-19 | Gene contenant des microsatellites polymorphiques de type cag, diagnostic de maladies psychiatriques et usages therapeutiques de ce gene |
| PCT/CA1998/000884 WO1999015639A1 (fr) | 1997-09-19 | 1998-09-18 | Gene polymorphe contenant des unites de repetition cag et ses utilisations |
| BR9812254-1A BR9812254A (pt) | 1997-09-19 | 1998-09-18 | Gene polimórfico cag de repetição contida e seus usos |
| AU91495/98A AU757556B2 (en) | 1997-09-19 | 1998-09-18 | Polymorphic CAG repeat-containing gene and uses thereof |
| CA002303106A CA2303106A1 (fr) | 1997-09-19 | 1998-09-18 | Gene polymorphe contenant des unites de repetition cag et ses utilisations |
| JP2000512932A JP2001517432A (ja) | 1997-09-19 | 1998-09-18 | 多形性ｃａｇ繰り返しを含む遺伝子およびその使用 |
| EP98943607A EP1015574A1 (fr) | 1997-09-19 | 1998-09-18 | Gene polymorphe contenant des unites de repetition cag et ses utilisations |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2216057 CA2216057A1 (fr) | 1997-09-19 | 1997-09-19 | Gene contenant des microsatellites polymorphiques de type cag, diagnostic de maladies psychiatriques et usages therapeutiques de ce gene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2216057A1 true CA2216057A1 (fr) | 1999-03-19 |
Family
ID=4161505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2216057 Abandoned CA2216057A1 (fr) | 1997-09-19 | 1997-09-19 | Gene contenant des microsatellites polymorphiques de type cag, diagnostic de maladies psychiatriques et usages therapeutiques de ce gene |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1015574A1 (fr) |
| JP (1) | JP2001517432A (fr) |
| AU (1) | AU757556B2 (fr) |
| BR (1) | BR9812254A (fr) |
| CA (1) | CA2216057A1 (fr) |
| WO (1) | WO1999015639A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19835910C1 (de) * | 1998-08-07 | 2000-05-04 | Deutsches Krebsforsch | Gen isoliert auf dem kurzen Arm des menschlichen Chromosoms 17 |
| AU8898001A (en) | 2000-09-08 | 2002-03-22 | Univ Iowa State Res Found Inc | Novel prkag3 alleles and use of the same as genetic markers for reproductive andmeat quality traits |
| GB0228079D0 (en) * | 2002-12-02 | 2003-01-08 | Laxdale Ltd | Huntington's Disease |
| WO2008032056A2 (fr) * | 2006-09-16 | 2008-03-20 | Genophrenix Limited | Marqueurs pour maladie |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5834183A (en) * | 1993-06-29 | 1998-11-10 | Regents Of The University Of Minnesota | Gene sequence for spinocerebellar ataxia type 1 and method for diagnosis |
| EP0873132A4 (fr) * | 1995-11-17 | 2002-09-18 | Univ British Columbia | PROTEINE AYANT UNE INTERACTION AVEC LE GENE DE LA MALADIE DE HUNTINGTON, ADNc CODANT CETTE PROTEINE ET ANTICORPS CONTRE CELLE-CI |
-
1997
- 1997-09-19 CA CA 2216057 patent/CA2216057A1/fr not_active Abandoned
-
1998
- 1998-09-18 JP JP2000512932A patent/JP2001517432A/ja active Pending
- 1998-09-18 AU AU91495/98A patent/AU757556B2/en not_active Ceased
- 1998-09-18 WO PCT/CA1998/000884 patent/WO1999015639A1/fr active IP Right Grant
- 1998-09-18 BR BR9812254-1A patent/BR9812254A/pt not_active Application Discontinuation
- 1998-09-18 EP EP98943607A patent/EP1015574A1/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| BR9812254A (pt) | 2002-07-09 |
| AU757556B2 (en) | 2003-02-27 |
| JP2001517432A (ja) | 2001-10-09 |
| WO1999015639A1 (fr) | 1999-04-01 |
| AU9149598A (en) | 1999-04-12 |
| EP1015574A1 (fr) | 2000-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rietschel et al. | Genome-wide association-, replication-, and neuroimaging study implicates HOMER1 in the etiology of major depression | |
| Sequeira et al. | Implication of SSAT by gene expression and genetic variation in suicide and major depression | |
| Zimoń et al. | Dominant GDAP1 mutations cause predominantly mild CMT phenotypes | |
| Wendland et al. | A haplotype containing quantitative trait loci for SLC1A1 gene expression and its association with obsessive-compulsive disorder | |
| Enoch et al. | Dimensional anxiety mediates linkage of GABRA2 haplotypes with alcoholism | |
| Konradi et al. | Mitochondria, oligodendrocytes and inflammation in bipolar disorder: evidence from transcriptome studies points to intriguing parallels with multiple sclerosis | |
| de Lara et al. | Effect of tryptophan hydroxylase-2 gene variants on suicide risk in major depression | |
| Michelon et al. | Association study of the INPP1, 5HTT, BDNF, AP-2β and GSK-3β GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder | |
| Aoki-Suzuki et al. | A family-based association study and gene expression analyses of netrin-G1 and-G2 genes in schizophrenia | |
| Saito et al. | Analysis of monoamine oxidase A (MAOA) promoter polymorphism in Finnish male alcoholics | |
| Hong et al. | Evidence of missense mutations on the neuregulin 1 gene affecting function of prepulse inhibition | |
| Sekiguchi et al. | ARHGAP10, which encodes Rho GTPase-activating protein 10, is a novel gene for schizophrenia risk | |
| Radel et al. | Haplotype-based localization of an alcohol dependence gene to the 5q34 γ-aminobutyric acid type A gene cluster | |
| Wilkie et al. | A splice site polymorphism in the G-protein β subunit influences antidepressant efficacy in depression | |
| Ross et al. | Genetic variation of Omi/HtrA2 and Parkinson's disease | |
| US20150278438A1 (en) | Genetic predictors of response to treatment with crhr1 antagonists | |
| US10837062B2 (en) | Method for predicting a treatment response to a CRHR1 antagonist and/or a V1B antagonist in a patient with depressive and/or anxiety symptoms | |
| Gao et al. | DNA methylation and gene expression of matrix metalloproteinase 9 gene in deficit and non-deficit schizophrenia | |
| Hong et al. | Case-control and family-based association studies between the neuregulin 1 (Arg38Gln) polymorphism and schizophrenia | |
| Manso et al. | Variants within the nitric oxide synthase 1 gene are associated with stroke susceptibility | |
| JP5828407B2 (ja) | 精神疾患の検査方法および精神疾患用の検査キット | |
| Oswald et al. | Lack of association between the 5HT2A receptor polymorphism (T102C) and unipolar affective disorder in a multicentric European study | |
| Gaweda-Walerych et al. | PARK2 variability in Polish Parkinson’s disease patients-interaction with mitochondrial haplogroups | |
| CA2216057A1 (fr) | Gene contenant des microsatellites polymorphiques de type cag, diagnostic de maladies psychiatriques et usages therapeutiques de ce gene | |
| Kim et al. | Association of a synonymous GAT3 polymorphism with antiepileptic drug pharmacoresistance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |